Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the Agricultural Health Study. Issue 10 (6th July 2015)

• Record Type: Journal Article
• Authors: Lerro, Catherine C; Koutros, Stella; Andreotti, Gabriella; Friesen, Melissa C; Alavanja, Michael C; Blair, Aaron; Hoppin, Jane A; Sandler, Dale P; Lubin, Jay H; Ma, Xiaomei; Zhang, Yawei; Beane Freeman, Laura E
• Is Part Of: Occupational and environmental medicine. Volume 72:Issue 10(2015)
• Page Start: 736
• Page End: 744
• Publication Date: 2015-07-06
• Subjects: Medicine, Industrial -- Periodicals; Environmental health -- Periodicals; 616.980305
• DOI: 10.1136/oemed-2014-102798
• Languages: English
• ISSNs: 1351-0711

Abstract

Abstract : Objectives: Organophosphates (OPs) are among the most commonly used insecticides. OPs have been linked to cancer risk in some epidemiological studies, which have been largely conducted in predominantly male populations. We evaluated personal use of specific OPs and cancer incidence among female spouses of pesticide applicators in the prospective Agricultural Health Study cohort. Methods: At enrolment (1993–1997), spouses provided information about ever use of specific pesticides, including 10 OPs, demographic information, reproductive health history and other potential confounders. We used Poisson regression to estimate relative risks (RRs) and 95% CIs for all cancers diagnosed through 2010 for North Carolina and through 2011 for Iowa. Results: Among 30 003 women, 25.9% reported OP use, and 718 OP-exposed women were diagnosed with cancer during the follow-up period. Any OP use was associated with an elevated risk of breast cancer (RR=1.20, 95% CI 1.01 to 1.43). Malathion, the most commonly reported OP, was associated with increased risk of thyroid cancer (RR=2.04, 95% CI 1.14 to 3.63) and decreased risk of non-Hodgkin lymphoma (RR=0.64, 95% CI 0.41 to 0.99). Diazinon use was associated with ovarian cancer (RR=1.87, 95% CI 1.02 to 3.43). Conclusions: We observed increased risk with OP use for several hormonally-related cancers, including breast, thyroid and ovary, suggesting potential for hormonally-mediated effects. This study represents the first comprehensive analysis of OP use and cancer risk among women, and thus demonstrates a need for further evaluation.